Consider ZOLADEX for your appropriate patients with advanced prostate cancer. ZOLADEX is a gonadotropin-releasing hormone (GnRH) agonist indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.
ZOLADEX is also indicated for use in the palliative treatment of advanced carcinoma of the prostate. For the management of advanced prostate cancer, ZOLADEX is intended for long-term administration unless clinically inappropriate.
ZOLADEX is available in two dosages. At a dose of 10.8 mg, ZOLADEX should be administered subcutaneously every 12 weeks into the anterior abdominal wall below the navel line, using an aseptic technique. At a dose of 3.6 mg, ZOLADEX should be administered subcutaneously every 28 days. While a delay of a few days is permissible, every effort should be made to adhere to the dosing schedule (every 12 weeks for the 10.8-mg depot and every 28 days for the 3.6-mg depot). Instructions for proper administration are demonstrated in the administration video.
The most commonly observed adverse reactions during ZOLADEX treatment for prostatic carcinoma were due to the expected physiological effects from decreased testosterone levels. The most common adverse reactions (incidence of >5% in prostate clinical trials) were:
In the locally advanced carcinoma of the prostate clinical trial, additional adverse event data were collected for the combination therapy with radiation group during both the hormonal treatment and hormonal treatment plus radiation phases of this study. Adverse experiences (incidence >5%) in both phases of this study were hot flashes (46%), diarrhea (40%), nausea (9%), and skin rash (8%). Treatment with ZOLADEX and flutamide did not add substantially to the toxicity of radiation treatment alone.
There are 3 easy ways to order ZOLADEX with the Direct Purchase Program. Choose the ordering method that best suits your needs.
ZOLADEX is ready to use. You do not need to refrigerate or premix ZOLADEX prior to administering the depot.
If you have other questions about ZOLADEX, please contact AstraZeneca, 8:00 AM to 6 PM, EST at 1-800-236-9933.
Understanding prostate cancer and treatment options provides information for patients about prostate cancer, its various stages, treatment options, and the effects it may have on a patient’s life.
Download the booklet here.
See and share the answers to frequently asked questions about ZOLADEX that patients may ask. These answers can help patients understand what ZOLADEX is, how it works, and what they may expect from therapy with ZOLADEX for advanced prostate cancer.
The following list of resources is provided as a convenience to you. AstraZeneca takes no responsibility for the content of, or services provided by, these resources and makes no representation as to the accuracy or completeness of any information provided by these resources. AstraZeneca shall have no liability for any damage or injuries of any kind arising from the information provided by the resources listed. The descriptions of the organizations are all directly from their respective Web sites.
Professional resources to support you
The American Urological Association is a premier urologic association, providing invaluable support to the urologic community. Their mission is to promote the highest standards of urological clinical care through education, research, and the formulation of health care policy.
The National Cancer Institute is part of the National Institutes of Health. The NCI is the federal government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice.
Resources to help you support your patients
The American Cancer Society is the largest volunteer organization in the United States and is committed to saving lives from cancer by helping people stay well, helping people get well, finding cures, and fighting back against cancer. There are 900 local offices nationwide to deliver lifesaving programs and services at the community level.
The Urology Care Foundation is committed to advancing urologic research and education to improve patients’ lives. The UCF is the official foundation of the American Urological Association and was formerly known as the AUA Foundation.
CancerCare is a national nonprofit organization that provides free professional support services to anyone affected by cancer: people with cancer, caregivers, children, loved ones, and the bereaved. CancerCare programs—including counseling, education, financial assistance, and practical help—are provided by trained oncology social workers and are completely free of charge. Founded in 1944, CancerCare provides individual help to 1 million people each year throughout the US.
The Men’s Health Network provides information about disease prevention, screening programs, and disease education materials for a number of diseases affecting men’s health. The MHN, which currently has a board of advisors including more than 800 physicians and key thought leaders, was founded in 1992 by a group of health professionals and others interested in improving the health and well-being of men, boys, and families.
The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research to fund better treatments and a cure for prostate cancer. PCF pursues its mission by soliciting and selecting promising research programs and rapid deployment of resources. Founded in 1993, the PCF has raised more than $370 million and has provided funding for more than 1500 research projects at nearly 200 institutions worldwide.
The Prostate Conditions Education Council provides information on prostate health. The Council, founded in 1989, is made up of a consortium of leading physicians, health educators, scientists, and prostate cancer advocates. The aim of the Council is to provide information, conduct nationwide screenings for men, and perform research that will aid in the detection and treatment of prostate and men’s health conditions.
The Prostate Net develops and maintains an interactive network of educational tools and services for consumers. These services are offered to educate, inform, and motivate consumers to make informed choices about prostate cancer and other prostate diseases.
This education and support network includes 325 support group chapters worldwide. They provide men and their families with free information, materials, and peer-to-peer support so they can make informed choices on detection, treatment options, and coping with ongoing survivorship.
ZERO – The End of Prostate Cancer is a national nonprofit organization with the mission to end prostate cancer. They lead the fight to end the disease by advancing research, encouraging action, and providing education and support to men and their families.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.